OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.56
+2.20%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.53
From 52W high−51.52%
Volume416051.00
Market cap$103.47M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.53
From 52W high
−51.52%
Volume
416051.00
Market cap
$103.47M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
48.4
MomentumView details →
1D Return
+2.20%
YTD Return
−11.72%
SummaryUpdated Jun 1, 2026
OnKure Therapeutics, Inc. (NASDAQ:OKUR) is a clinical-stage biotechnology company founded in 2011 and headquartered in Boulder, Colorado. The company specializes in discovering and developing precision oncology medicines, with a particular focus on creating selective inhibitors of histone deacetylases (HDACs) for treating various forms of cancer. OnKure went public through a merger transaction and currently trades on NASDAQ, representing one of the smaller players in the competitive oncology drug development space.
Similar companies
Latest newsMore news →
OnKure Therapeutics repriced outstanding stock options for its CEO, CMO, and CFO to $4.14 per share, effective August 7, 2026, subject to an 18-month retention requirement.84d agoOnKure Therapeutics, Inc. elected R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers as Class II directors, effective June 3, 2026.154d ago